Other languages Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
1,003 ^USD	+0.22%		+2.33%	+14.19%

Jun. 05	Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing	MT
Jun. 05	Transcript : Regeneron Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 08:30 AM

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing	Jun. 05
ETF de la semana: Las energías limpias vuelven a despegar	Jun. 05
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier	Jun. 03
Fibrogen, Inc. Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate FibroGen's Immuno-Oncology Assets, Fg-3175 (Anti-Ccr8), in Upcoming Clinical Trials	Jun. 03
ETF de la semana: Las materias primas siguen teniendo potencial	May. 31
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review	May. 31
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee	May. 31
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months	May. 31
US-Prüfung für Sanofi-Arznei Dupixent um drei Monate verlängert	May. 31
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD	May. 31
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation	May. 31
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing	May. 29
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer	May. 23
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075	May. 23
ETF de la semana: Los “utilities” desempeñan un papel en la aparición del AII	May. 23
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing	May. 22
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate	May. 20
Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine	May. 20
Compañías que se deben tener muy en cuenta por técnico este lunes en Wall Street	May. 20
Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing	May. 17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Other languages

Filters